Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint
Castagnetti F et al. Leukemia, November 2025 (epub ahead of print) – open access publication
Link to full abstract